



Human
Fertilisation &
Embryology
Authority

Annual report and accounts 2017/18



Human Fertilisation and Embryology Authority

Annual report and accounts 2017/18

Presented to Parliament pursuant to sections 6 and 7 of the Human Fertilisation and Embryology Act 1990 as amended by paragraph 3 of schedule 7 of the Human Fertilisation and Embryology Act 2008.

Ordered by the House of Commons to be printed on **6 July 2018**.



© Crown copyright 2018

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3

Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at www.gov.uk/government/publications

Any enquiries regarding this publication should be sent to us at: Human Fertilisation and Embryology Authority, 10 Spring Gardens, London, SW1A 2BU enquiriesteam@hfea.gov.uk

ISBN 978-1-5286-0626-4

CCS0618969246

07/18

Printed on paper containing 75% recycled fibre content minimum

Printed in the UK by the APS Group on behalf of the Controller of Her Majesty's Stationery Office

Contents

Chief Executive's foreword	5
Performance	6
Overview	7
Performance analysis	12
Accountability	16
Corporate governance report	17
Remuneration report	26
Parliamentary accountability and audit report	36
Financial statements	41

Chief Executive's foreword

Our vision is a simple one: high quality care for everyone affected by fertility treatment. This vision is at the heart of our three-year strategy for 2017-2020. One year in, I am delighted to say that we are making real progress.

Our new clinic portal and website were launched in April 2017. Our new website is easy to use from both desktop and mobile devices and is focussed on the needs of patients. It includes a wide range of up to date scientific information, providing clear and unbiased information about core IVF treatments and a range of the most commonly offered add-ons. We are determined to put patients in a position where they can fully understand the treatment choices that are offered to them.

Our aim, throughout our activities, has been to collect and use our data, and to communicate with our audiences, as effectively as possible. In order to capitalise fully on the advancements achieved through the Information for Quality Programme over the past three years, we restructured the HFEA's staffing, in April 2017, creating a new Intelligence team and re-shaping other functions. This reconfiguration will ensure we have the right skills and capacity in place to enable us to make full use of our new tools and to implement a newly agreed intelligence strategy in 2018/19 and beyond.

When the new Register and electronic data interchange systems are also fully complete, in autumn 2018, we will be even better equipped to collect and use our data in new and exciting ways.

In January 2018, the Authority approved a new information strategy, setting out how we will analyse, publish and use our data to improve the quality of the information we produce and, ultimately, to provide a sharper focus in our regulatory work. With the aim of improving the chances of successful treatment, we have been publishing more information in our annual Fertility Trends report, and focusing on success rates through inspection reports and risk tool alerts.

We carried out a full programme of clinic inspection, audit and licensing activities, increasing our emphasis on consistent standards and safety. Through our inspection activities, we maintained our focus on quality and safety, focusing in particular on shortcomings in the taking and recording of consents, learning from incidents, medicines management, data submission, multiple birth rates, and the information clinics publish on their own websites. We also began to work with commercial groups of clinics, so as to improve quality, consistency and compliance on a group-wide basis, as relevant.

If we are to see an improvement in the overall quality of treatment offered in clinics we need to see a greater openness across the sector to research. We need to see more world class data and embryo research and a greater use of clinical trials. In 2017/18 we completed two projects on research – one to ensure that clinics explain data research well to patients, and record consent accurately, and the other to promote and explain embryo research findings and improve the explanatory material available to patients about donating unused embryos for research purposes. We also continued to respond to requests from researchers for access to Register data for research purposes.

The fertility sector in the UK is largely a high performing one. But it could do better. As the dedicated regulator for the sector we are determined to focus our energies on driving through performance improvements for the good of all who need fertility services.

Performance

Overview

The Human Fertilisation and Embryology Authority (HFEA) is the regulator of fertility treatment and human embryo research in the UK. We are a Non-Departmental Public Body sponsored by the Department of Health and Social Care (DHSC) incorporated and domiciled in England. Our registered office is 10 Spring Gardens, London SW12BU.

Our role includes licensing and setting standards for clinics and research centres and providing a range of information for the public, particularly people seeking treatment, donor-conceived people and donors.

In the past year, we began to deliver our three-year strategy for 2017-2020, with an emphasis on making full use of our Clinic Portal, website and data so as to improve quality for patients.

Our new Clinic Portal and website were launched in 2017, as part of our Information for Quality programme. When the new Register and electronic data interchange systems are also fully complete, in autumn 2018, we will be even better equipped to collect and use our data in new and exciting ways.

Our aim, throughout our activities, has been to collect and use our data and to communicate with our audiences as effectively as possible. Our engagement with stakeholders has been extensive, including regular meetings with professional stakeholder groups, workshops throughout the year on particular policy developments or the Code of Practice, our annual conference, and user engagement to help us test and develop our new services. Alongside our new website we have a twitter account and Facebook page, and we are planning a national patient survey in 2018.

In order to capitalise fully on the advancements achieved through the Information for Quality programme over the past three years, we also restructured our workforce, in April 2017, creating a new Intelligence team and re-shaping other functions. This reconfiguration will ensure we have the right skills and capacity in place to enable us to make full use of our new tools and to implement a newly agreed intelligence strategy in 2018/19 and beyond.

Following the restructuring, we involved our staff in the development of a people strategy setting out how we will attract and retain the skills and talent we need in order to deliver our strategic vision. Our people strategy describes our core values, which are:

- we care about our people
- we are expert and are knowledgeable about our business
- we are professional; we take pride in our work and act in an accountable way.

Our people strategy acknowledges that our success as an organisation depends on having skilled and motivated employees.

Our legislation and functions

Our regulatory role and functions are set by two pieces of legislation:

- The Human Fertilisation and Embryology Act 1990 (as amended) – generally referred to as ‘the 1990 Act’; and
- The Human Fertilisation and Embryology Act 2008 (‘the 2008 Act’).

Under this legislation our main statutory functions are:

- to license and inspect clinics carrying out in vitro fertilisation and donor insemination treatment;
- to license and inspect centres undertaking human embryo research;
- to license and inspect the storage of gametes (eggs and sperm) and embryos;
- to publish a Code of Practice, giving guidance to clinics and research establishments about the proper conduct of licensed activities;
- to keep a register of information about donors, treatments and children born as a result of those treatments;
- to keep a register of licences granted;
- to keep a register of certain serious adverse events or reactions;
- to investigate serious adverse events and serious adverse reactions and take appropriate control measures.

In addition to these specific statutory functions, the legislation also gives us more general functions, including:

- promoting compliance with the requirements of the 1990 act (as amended), the 2008 act and the Code of Practice;
- maintaining a statement of the general principles that we should follow when conducting our functions and by others when carrying out licensed activities;
- observing the principles of best regulatory practice, including transparency, accountability, consistency, and targeting regulatory action where it is needed;
- carrying out our functions effectively, efficiently and economically;
- publicising our role and providing relevant advice and information to donor-conceived people, donors, clinics, research establishments and patients;
- reviewing information about:
 - human embryos and developments in research involving human embryos
 - the provision of treatment services and activities governed by the 1990 act (as amended)
- advising the Secretary of State for Health and Social Care on developments in the above fields, upon request.

We also function as one of the two UK competent authorities for the European Union Tissues and Cells Directive (EUTCD). This directive regulates the donation, procurement, testing, processing, preservation and distribution of human tissue and cells for human application.

Delivery in 2017/18

Our objectives for 2017/18 were as follows.

Safe, ethical, effective treatment

We carried out a full programme of clinic inspection, audit and licensing activities, increasing our emphasis on consistent standards and safety. We carried out additional inspections at a number of clinics after a media investigation alleged poor practices in a number of clinics. We also began a conversation

with the sector about clinic leadership, with the aim of putting in place new incentives to encourage and support excellent clinic leadership.

We maintained our strong focus on learning from incidents, adverse events and complaints from patients and published our annual review of clinic incidents in November 2017. This year work on incidents was part of our first State of the Sector report, which provided more information than ever before on the performance of the fertility sector for clinics and the wider public.

Throughout the year, our licensing committees considered inspection reports and applications for preimplantation genetic diagnosis (PGD), human leukocyte antigen (HLA) testing, and, for the first time, mitochondrial donation – the licensing of such treatments is a world first in a regulated environment.

Our website includes a wide range of up-to-date scientific information to provide clear and unbiased information for patients about treatments and add ons. And our annual horizon scanning process helped to ensure that our policy developments and website material are informed by expert input and an understanding of current scientific issues and future developments.

We seek to encourage an enquiring culture and responsible innovation in clinics and to improve the overall quality of treatment by engendering world class data and embryo research and clinical trials. In 2017/18 we completed two projects on research – one to ensure that clinics explain data research well to patients, and record consent accurately, and the other to promote and explain embryo research findings and improve the explanatory material available to patients about donating unused embryos for research purposes. We also continued to respond to requests from researchers for access to Register data for research purposes.

Consistent outcomes and support

We provided advice and information to patients about accessing treatment and donation via our website. We also worked with professional stakeholders (such as the British Fertility Society (BFS)) to put patients in touch with better information and services when they first realise they may have a fertility issue.

Through our inspection activities, we maintained our focus on quality and safety, focusing in particular on shortcomings in the taking and recording of consents, learning from incidents, medicines management, data submission, multiple birth rates, and the information clinics publish on their own websites. We also began to work with commercial groups of clinics to improve quality, consistency and compliance on a group-wide basis, as relevant.

We have worked with NHS England on a piece of work led by them on price benchmarking, with the aim of assisting NHS commissioners in securing fair prices and effective fertility services for patients. This collaborative work will continue in 2018/19.

We began a project on the emotional experience of care before, during and after treatment, working with professional stakeholders to bring about improvement. Proposed changes will be incorporated into the next edition of the Code of Practice in 2018. We also evaluated the second year of a three-year pilot of counselling support services for applicants to the Register.¹

¹ Explanatory note: A donor-conceived person aged 18 or above is entitled to access identifying information about their donor, providing the donor has asked for their right to anonymity to be removed.

With the aim of improving the chances of successful treatment, we have been publishing more information in our annual Fertility trends report, and focusing on success rates through inspection reports and risk tool alerts. In the coming year we plan to do further work on success rates.

At the end of the business year, we implemented new European Union (EU) requirements relating to the import and coding of donor eggs and sperm. To ensure we're fully compliant, new processes and certifications will be introduced.

Improving standards through intelligence

In January 2018, the Authority approved a new information strategy, setting out how we will analyse, publish and use our data to improve the quality of the information we produce and, ultimately, to provide a sharper focus in our regulatory work. This followed on from the creation of a new Intelligence team in our organisational re-shaping in 2017. The information strategy sets out much of our strategic delivery in 2018/19.

We maintained our role as the UK's competent authority for assisted reproductive technologies in the EU, participating in two meetings and implementing associated EU decisions such as the new requirements on certifying imports of eggs, sperm and embryos.

In addition to our programme of improvement work on the Register infrastructure, which will conclude this year, we maintained the Register of treatments and outcomes throughout the year and worked with clinics to ensure accurate reporting of data. We also continued to publish the information we hold, and to respond to a range of enquiries from patients, clinics and central Government.

Risks as at 31 March 2018

Below are the main risks we face that, should they occur, would have the greatest material effect on the functioning of the HFEA as a whole.

By considering such risks, we can assess the continuing viability of our strategy and business plan against changes in circumstance, and make adjustments when necessary. This does not mean we expect the risks to materialise – instead it indicates that these are areas of risk of which we need to be aware and to consider our response to in order to perform our role effectively.

Further information on our approach to managing strategic risks can be found in the governance statement.

Risk area	Main strategic risks monitored	Related strategic theme
Regulatory effectiveness	Translation of data into quality Loss of regulatory authority	Improving standards through intelligence
Effective communications	Messaging, engagement and information provision	Safe, ethical effective treatment; consistent outcomes and support
Cyber security	Security	

	Infrastructure weaknesses	Safe, ethical effective treatment; consistent outcomes and support; Improving standards through intelligence
Financial viability	Income and expenditure	Consistent outcomes and support
Capability	Knowledge and capability	Safe, ethical effective treatment; consistent outcomes and support; Improving standards through intelligence
Organisational change	Change-related instability	Improving standards through intelligence
Legal challenge	Resource diversion	Safe, ethical, effective treatment

Going concern

We consider the use of the going concern basis of accounting is appropriate because there are no material uncertainties related to events or conditions that may cast significant doubt about the ability of the organisation to continue as a going concern.

Performance analysis

Measuring performance

Each year, we agree a business plan with our sponsor department, the Department of Health and Social Care (DHSC) that includes strategic aims, high level objectives and key performance indicators covering delivery of our strategic plan.

We record performance against key performance indicators monthly and review achievement and action needed at the Corporate Management Group (CMG) meeting. A report is made to the Authority every two months and DHSC every quarter.

Analysis of performance in 2017/18

Performance indicators (PI)	Target 2017/18	PI	Target 2016/17	PI
A: Compliance				
Average number of working days taken for the whole licensing process, from the day of inspection to the decision being communicated to the centre	70 working days	54.5 working days	70 working days	65.2 working days
B: Communication and information				
Opening the Register requests responded to within 20 working days	100%	100% (238 requests)	100%	100% (255 requests)
Requests for contributions to Parliamentary questions (PQs) answered within Department of Health deadlines.	100%	100% (44/44 PQs within deadline)	100%	100% (55/55 PQs within deadline)
C: Corporate				
Staff sickness absence rate (%)	No more than 2.5%	1.4%	No more than 2.5%	1.6%
Cash and bank balance at end of the year	To continue to move further towards the Department of Health and Social Care's agreed minimum cash reserve of £1.52m	£3.23m² (increased from £2.35m in 16/17)	To continue to move further towards the Department of Health and Social Care's agreed minimum cash reserve of £1.52m	£2.35m (increased from £2.16m at the end of 15/16)
Percentage of invoices paid within 10 calendar days	70% paid within 10 days	93%	70% paid within 10 days	94%

² Cash and bank balance were higher at year end largely due to budget limitations on spending, our receipts and higher accruals of £535k which include costs for our rent of £286k, compared to 2016/17 £284k.

Debts collected within 60 calendar days	85%	89%	85%	90%
---	-----	------------	-----	-----

Financial review

We are funded from two main sources:

- licence and treatment fees from the establishments we licence (85%), and
- grant-in-aid from the DHSC (15%).

72% of our expenditure is on staff costs. Our other administrative costs include spend on legal costs (5%) and facilities expenses (6%).

Summary position as at 31 March 2018

	2017/18	2016/17
	£'000s	£'000s
Expenditure		
Staff costs	4,232	3,816
General administrative costs	1,670	1,597
Total expenditure	5,902	5,413
Income		
Licence fees	5,305	5,323
Other income	97	26
Total income ³	5,402	5,349
Net (expenditure)/income before interest and tax	(500)	(64)

Our financial results are included in the accounts on pages 42 to 60 and show that the deficit before interest and tax was £499,305 (2016/17 a deficit of £64,309). This significant increase from last year is due to an increase in our staff costs relating to Agency staff (£467k compared to £145k in 2016/17). The use of agency staff was necessary to back-fill vacancies and staff working on the Digital Projects. This is the only area that has seen a significant increase.

The DHSC provided grant-in-aid towards the financing of resource expenditure of £933,000 (2016/17: £938,000) and £500,000 cash allocation towards the funding of the Digital Projects (2016/17: £467,000). Taking into account the resource financing, and after interest and tax, we had a surplus of £438,392.

Our total costs are increased from last year due to the use of Agency staff as mentioned previously. Other areas have remained largely the same with some downward movement in our legal fees (28%) and audit fees (17%). Costs incurred pertaining to the Digital Projects – which is the second phase of the

³ This does not include interest income

Information for Quality programme that involves updating our systems and the way we use data, have been transferred to our balance sheet under the heading Assets under construction to the value of £475k.

Cash reserves have increased significantly from the previous financial year. A combination of surplus fee income and significant working capital movements has led to an increase in cash of £875k. The uncertainty in relation to treatment volumes, which drives fee income, means that predicting income in any given financial year is difficult. We have developed a new forecasting model to improve our ability to forecast volumes and have committed to undertaking a review of licence fees once our model has matured.

Supplier payments

We aim to pay all undisputed invoices in accordance with suppliers' terms of payment, which are usually within 30 days. During the financial year, we settled 100% of all invoices received within 30 days with a value of £2,369,114 (2016/17 99% with a value of £1,917,125).

Our staff

Recruitment

All appointments are made in accordance with our recruitment and selection policy so that they are made on the basis of merit and in accordance with equal opportunities.

Learning and development

We actively promote the development of our staff and encourage them to take five days a year learning. We subscribe to Civil Service Learning which provides courses and resources for developing skills to all UK civil servants. This supports a blended approach which is convenient and cost-effective. Individual needs are set out in personal development plans and are met through appropriate means, including e-learning, face-to-face learning and taking part in projects, coaching and job shadowing. We recently revised our policy on the allocation of our training budget, giving more flexibility to Heads of department to authorise a range of types of learning.

Staff engagement and wellbeing

We promote staff engagement through various channels including regular all-staff and team meetings, our annual staff conference, a monthly staff bulletin and ad hoc working groups. Staff surveys provide formal mechanism to obtain and respond to staff feedback. In 2017/18, 71% (2016/17, 86%) of staff responded to the staff survey, which although a reduction on last year can largely be explained by recent staff changes. Some 84% of our staff (2016/17, 90%) reported a clear understanding of the HFEA's purpose – which provides a very solid foundation which we can build on.

Disabled employees

We have long achieved ✓✓ 'positive about disabled people' disability symbol status. We have a specific policy of inviting to interview any candidate with a disability who meets essential criteria. Support is provided for all staff who have, or develop, a disability including making any reasonable adjustments to the workplace or work processes and having advice available through the occupational health service.

Equality Act 2010 – equality and diversity on pay

We remain compliant with the requirements of the Equality Act 2010 and we continue collectively to ensure, throughout the year, that we fulfil our obligations under the Equality Act. All posts are systematically evaluated, against a formal job evaluation scheme 'Paypoints II', aiming to ensure that salaries are internally consistent, fair and equitable.

Our gender breakdown at 31 March 2018, of Authority members, permanent and seconded staff, is as follows:

	Male	Female	Total
Authority members	4	7	11
Senior Management Team (SMT)	3	1	4
All staff (including SMT, excluding Authority)	13	51	64

Social, community, sustainability, human rights and environmental issues

We are sub-tenants of the National Institute for Health and Care Excellence (NICE) in Spring Gardens in central London. We collaborate with NICE on a number of issues, including health and safety services - we follow their lead on fire evacuation procedures and fire warden liaison.

We recycle paper, card, glass, plastic cups, containers and bottles, metal cans and toner cartridges. There are two multi-function devices (for secure printing, scanning and photocopying) that are pre-set to print on both sides of the paper and in black and white. IT equipment is re-used and working lives extended where possible, and is switched off when not in use. Surplus equipment is either sold or donated. Many staff are enabled to work from home, reducing the impact on the environment through less travelling.

We are aware of the green agenda in relation to procurement and we use the Crown Commercial Service and other frameworks which have sustainability factored in.

We manage our corporate responsibility by providing processes and policies which include but are not limited to policies on diversity; protecting human rights, equal opportunities, dignity at work and anti-fraud including anti bribery and corruption.



Peter Thompson
Chief Executive
Accounting Officer

27 June 2018

Accountability

Corporate governance report

Directors' report

Our board (the Authority)

Our board is normally made up of 12 members appointed through an open public process, although for much of the year we had to cope with 11 members. We now have an agreement from the DHSC to increase to 13 members in 2018/19 which will allow us to recruit additional expertise to the board. Below are details of the current and out-going Authority members during the 2016/17 financial year. Biographies for each can be found on our website.

Authority member	Appointment start date	Appointment end date
Sally Cheshire (Chair)	7 November 2006	31 March 2020 (re-appointed 13 September 2016)
Andy Greenfield	9 November 2009	31 December 2018
Lee Rayfield	23 April 2012	22 July 2018 (extended)
Kate Brian	12 November 2014	11 November 2020 (re-appointed 27 September 2017)
Anthony Rutherford	12 November 2014	11 November 2020 (re-appointed 27 September 2017)
Yacoub Khalaf	30 April 2015	31 March 2021 (re-appointed 27 September 2017)
Margaret Gilmore (Deputy Chair)	30 April 2015	31 March 2021 (re-appointed 27 September 2017)
Anita Bharucha (Chair of AGC)	30 April 2015	31 March 2021 (re-appointed 27 September 2017)
Anne Lampe	1 February 2016	31 January 2019
Ruth Wilde	1 January 2016	31 December 2018
Bobbie Farsides	1 February 2017	31 January 2020

Senior Management Team

Our Chief Executive and directors, and their responsibilities, during 2017/18 are set out below.

Peter Thompson, Chief Executive		
HR		
Legal		
Richard Sydee ⁴ , Director of Finance and Resources	Clare Ettinghausen, Director of Strategy and Corporate Affairs ⁵	Nick Jones, Director of Compliance and Information
Budgeting	Governance and licensing	Inspection and clinical governance
Accounting	Regulatory policy	Business support
Financial control	Engagement and communications	Information and Register Development
Audit and risk assurance	Business planning	Network support
Facilities	Programme management	

Interests of Authority members and senior staff

We maintain a register of interests which is available on our website at www.hfea.gov.uk.

Pensions

Pension benefits are mainly provided by the Principal Civil Service Pension Scheme (PCSPS). We recognise the contributions payable for the year. Full details of the pension scheme are included in the Remuneration report.

Data incidents

Arrangements for data security and any personal data-related incidents are set out in the annual governance statement.

Our auditors

The Comptroller and Auditor General is appointed by statute to audit our financial statements. The fees of the National Audit Office are set out in note three to the accounts. No fees were incurred for non-audit work.

Disclosure of information to our auditors

I have taken all the necessary steps to make myself aware of any relevant audit information, and to establish that our auditors, the National Audit Office (NAO), are aware of that information. So far as I and the other directors are aware, there is no relevant audit information of which the NAO is unaware.

⁴ Richard Sydee is employed by the HFEA and is seconded to the Human Tissue Authority for 2.5 days per week.

⁵ Clare Ettinghausen replaced Juliet Tizzard on 29 January 2018

Statement of Accounting Officer's responsibilities

Under Section 6(1) of the Human Fertilisation and Embryology Act 1990 (as amended), we are required to prepare a statement of accounts for each financial year in the form, and on the basis determined by, the Secretary of State, advised by HM Treasury.

The accounts are prepared on an accruals basis, and must show a true and fair view of our state of affairs at the year-end, our net expenditure, changes in taxpayers' equity and cash flow for the financial year.

In preparing the accounts, I am required as the Accounting Officer is required to comply with the requirements of the Government financial reporting manual, and in particular to:

- observe the accounts directions issued by the Secretary of State, including the relevant accounting and disclosure requirements and apply suitable accounting policies on a consistent basis
- make judgements and estimates on a reasonable basis
- state whether applicable accounting standards, as set out in the Government financial reporting manual, have been followed and disclose and explain any material departures in the financial statements, and
- prepare the financial statements on a going concern basis as there are now no formal grounds to consider this inappropriate.

The Accounting Officer of the Department of Health (DHSC) has designated me, as the Chief Executive as the Accounting Officer for the organisation. My responsibilities include responsibility for the propriety and regularity of the public finances for which he is answerable, for keeping proper records and for safeguarding our assets, as set out in 'Managing public money' published by the HM Treasury.

I confirm that the annual report and accounts as a whole is fair, balanced and understandable and takes personal responsibility for the annual report and accounts and the judgements required for determining that it is fair, balanced and understandable.

I confirm that, as far as I am aware, there is no relevant audit information of which the entity's auditors are unaware, and I have taken all the steps that I ought to have taken to make myself aware of any relevant audit information and to establish that the entity's auditors are aware of that information.

Accounts direction

The statement of accounts is prepared in a form directed by the Secretary of State for Health dated 18 June 2007, in accordance with section six of the 1990 Act (as amended).

Authority statement

Our Senior Management Team (SMT), the Audit and Governance Committee and the Authority have reviewed the annual report and accounts. I confirm that the annual report and accounts are fair, complete and understandable and provide the information necessary for stakeholders to assess our performance.

Governance statement

This statement sets out our governance and control framework during 2017/18 and the risks to HFEA performance. It explains how I have discharged my responsibility, as Accounting Officer, to manage and control the HFEA's resources in 2017/18.

The picture is good, with strong performance from the Authority, committees and the executive, and a clean bill of health from internal audit. There have been changes at Executive level and these have been managed through the wider knowledge and continuity amongst the Authority and Directors. Our Digital Projects completed two key deliverables during 2017/18, with significant progress made, the programme will conclude in 2018/19 and provide significant improvements on our existing platforms.

Governance framework

Our governance framework is set out in the HFE Act 1990 (as amended) and its approved standing orders.

Our board (the Authority)

The Authority has 12 members (including one vacancy at present). There have been six Authority meetings in 2017/18, all of which were quorate. The Authority's meetings are open to the public and an audio recording of the meeting is on our website. The Authority has also held a number of workshops before its public meetings, which are used to discuss future strategy and other policy matters. In March 2018, we held our annual conference for fertility professionals.

The papers on which the Authority (and its committees) rely are subject to a rigorous internal assurance process, overseen by the relevant member of the SMT. Feedback from members of the Authority, and the annual review of committees, suggests that the papers are of high quality and accuracy.

Statutory and standing committees

The Authority has several committees to which it delegates a number of its functions. The following table sets out each committee alongside their frequency and attendance details.

Committee	Membership at 31 March 2018	Number of meetings 2017/18	Attendance rate
Authority	11	6	85%
Appointments Committee	3	2	100%
Audit and Governance Committee	4	4	100%
Executive Licensing Panel	9	25	100%
Licence Committee	5	6	90%

Committee	Membership at 31 March 2018	Number of meetings 2017/18	Attendance rate
Register Research Panel	3	1	100%
Remuneration Committee	3	1	100%
Statutory Approvals Committee	5	12	92%
Scientific and Clinical Advances Advisory Committee	5	3	60%

The Executive

The Authority and its committees are supported in their work by the Executive, led by the Chief Executive (the Authority's Accounting Officer) and three directors, collectively the Senior Management Team (SMT).

The SMT are:

Peter Thompson	Chief Executive
Richard Sydee	Director of Finance and Resources (shared with the HTA)
Nick Jones	Director of Compliance and Information
Clare Ettinghausen	Director of Strategy and Corporate Affairs

The Director of Finance and Resources (and the Head of Finance) are shared with the HTA, an arrangement that has been successfully in place for over 4 years. This year we undertook a formal review of the shared arrangements between the two organisations. In summary the review concluded that operationally the joint function provides good support and performance for both organisations, but that there are some areas in relation to workload, resilience and further opportunities for collaborative working that will be implemented during 2018/19. As Chief Executive, I am confident that the risks are being handled appropriately and effectively.

The SMT and Corporate Management Group (CMG) oversee the delivery of our business plan. CMG is chaired by the Chief Executive and attended by the directors and heads of department, and meets once a month as a minimum. It also considers strategic risks before the Audit and Governance Committee (see below).

The Executive's Programme Board oversees individual projects and ensures that suitable controls are in place. Risk assessment and management are substantial aspects of this oversight arrangement, with the project manager and sometimes also the project sponsor (usually a director) reporting to the Programme Board at regular intervals. In turn, the Programme Board reports to CMG every month, with a highlight report covering each live project.

Corporate governance

Like other ALBs in the health and care sector, we have a framework agreement with the DHSC which defines the critical elements of our relationship with them. The way in which we work with the DHSC, and

how we both discharge our accountability responsibilities effectively, is outlined in the agreement. The Chair and Chief Executive meet the Senior Departmental Sponsor (SDS) at the DHSC for a formal annual accountability review and informally throughout the year. In addition, the SMT meets other DHSC officials at quarterly intervals, and has regular contact as issues require. Representatives from the DHSC are also present as observers at Board meetings of the Authority and at the Audit and Governance Committee.

The operational objectives that help us deliver our corporate strategy are set out in the annual business plan. Drafts of this document are shared with the DHSC in advance and quarterly monitoring information is also submitted to them. Along with meetings with the SDS and other officials at the DHSC, this provides assurance that the delivery of objectives is on track.

Our system of corporate governance complies with the requirements of the 'Corporate governance in central Government departments: code of good practice', in so far as they relate to ALBs. It is designed to ensure that sufficient oversight of operational matters is held by our Authority and Audit and Governance Committee, while allowing for clear accountability and internal control systems at Executive level.

Effectiveness and performance

We have achieved our core statutory functions of licensing and regulating fertility clinics, maintaining a register of treatments and a Code of Practice, and increasing and informing choice for patients. In common with all public sector organisations, we have done so under continued pressure on our staff.

We look to improve and make more efficient the way in which we engage with significant matters of policy and operational delivery. One of the ways in which the Authority makes better use of its time is through 'workshop' sessions before full Authority meetings, *where the Authority has the opportunity to delve into issues that have arisen or are on the horizon*. This way of working makes more efficient and productive use of member and executive time and allows better informed decision-making.

This, along with the annual review of committee effectiveness and consequent changes to governance and standing orders, gives assurance that the exercise of our statutory functions is delegated appropriately and legally, adhering to the recommendations outlined in the Harris review.

Members of the Authority and the Chief Executive have their performance assessed by the Chair (or, in the case of the Chair, by the SDS). No issues of performance have been raised and as Chief Executive I am assured that the arrangements in place for internal control are robust and fit for purpose.

Annual reviews of committee effectiveness

As is good practice, every year our committees undertake a review of their effectiveness. In general, the feedback from the committees was good, with defensible, evidenced decisions being made on the basis of robust paperwork.

Highlights of Authority and committee reports

The Authority considered a wide variety of issues in 2017/18. *Its focus has been primarily on the development of the new Intelligence strategy, fertility trends, publication of the fertility sector report 2016/17 and investigations into clinics stemming from media interest.*

The Audit and Governance Committee continues to give the Authority assurance that financial and risk management systems are in place and of appropriate scrutiny to ensure adherence. The Audit and Governance Committee continues to take a theme-based approach to its meetings, giving it a broad

outlook over the organisation and its operations. It has exercised its delegated functions, including approval of this statement, on behalf of the Authority.

Our Licence Committee, Statutory Approvals Committee, and the Executive Licensing Panel have handled the core business of considering licence applications and issues, applications for embryo testing and applications for importing or exporting embryos, sperm and eggs. The levels of activity in these committees has increased significantly over the last year and we are reviewing how these committees are operated and supported during 2018/19

The Scientific and Clinical Advances Advisory Committee has provided high-quality advice and exercised its delegated functions appropriately.

The Remuneration and Appointments committees continue to consider matters pertaining to human resources, remuneration, and the appointment of external committee members and advisers.

Risk and capability

Given the variety and complexity of the risks we face, our overall appetite for risk is low. The framework we have in place to identify and manage risk is appropriate and allows for reasonable controls to be in place, without impacting on the successful delivery of our objectives.

A comprehensive description of current risk management procedures is set out in our risk policy that was reviewed in January and updated in February 2018.

Our system of internal risk management gives assurance that the risks we face when exercising our statutory functions are managed appropriately and mitigated against proportionately. Risks are formally managed at several different levels, as follows:

- strategic risk register – capturing risks to the delivery of our strategy and business plan
- operational risk logs – capturing team level risks to functional delivery
- project/programme risk logs – capturing risks to successful project delivery
- internal incidents system – an adjunct to the risk system, which enables understanding of, and corporate learning from, internal adverse events.

The Authority and its Audit and Governance Committee consider the strategic risk register, which is populated by CMG based on ongoing consideration of risks to delivering our strategy, including any major current operational risks. Teams each maintain a risk log capturing their own operational level risks, and the top risks are regularly shared at CMG risk meetings. This allows for the management of risk to be embedded in the organisation from the bottom up.

Projects are scrutinised by our Programme Board. Risk assessment and management are a substantial aspect of this oversight arrangement and the project manager (and sometimes also the project sponsor - usually a director) must report to the Programme Board at monthly intervals. In turn, the Programme Board reports to CMG every month, with a highlight report outlining progress, risks and issues for each live project.

The resources available for our wider program of work continues to be restrained by the wider public sector constraints on growth. Although we have seen an increase in our income this has not enabled us to increase expenditure on regulatory activity. We maintain our expenditure in line with budgets agreed with the Department of Health and Social Care and our stakeholders. This also impacts on our ability to respond or address emerging issues within the sector we regulate.

Our system of internal risk management gives assurance that the risks we face when exercising our statutory functions are managed appropriately and mitigated against proportionately.

Regulatory risk

We also take a risk-based approach to the way we regulate the fertility sector, in order to ensure that our regulatory action is targeted and proportionate. Our risk-based assessment tool allows such an approach and (like all other processes we use in carrying out our functions) is subject to a rigorous quality assurance regime, in line with the Macpherson review recommendations⁶.

Risk assessment

Systematic Regulatory risks such as the potential for poor quality or unsafe care, or any loss of our authority as a regulator is one of our key strategic risks which we maintain focus upon and track accordingly. Another important area of risk is the need to successfully deliver the Digital Projects and improve our engagement channels, the usage and accuracy of our Register information, and achieving promised efficiencies. Other risks include risks to our data or information accuracy, legal challenges, and our staff capacity and capability. Our ongoing mitigating activities are managed and monitored through the systems described earlier. The Digital Projects, once complete, will help in continuing to minimise the risk to our data and information, while our robust governance and decision-making arrangements mitigate against the controllable elements of the risk of legal challenge. Like all public sector organisations, we continue to face capacity and capability risks that we manage through good internal communications, staff engagement and our performance management process.

This year we have continued to review and amend our approach to cyber-risk and focussed on how secure our system and data are. This is an area that has increased relevance as we finalise our IT transformation programme due in large part to the number of high profile public sector IT security incidents that have occurred through 2017/18. Having commenced risk assurance mapping in early 2016, where we focussed on capability and capacity risks, we have found such exercises help us to assess the effectiveness of our risk control framework and identify any improvements we can make. We will continue to conduct similar exercises annually, in conjunction with our internal auditors.

Information management and security

As the holder of the statutory Register of fertility treatments, we take our responsibilities for information security most seriously and have a low tolerance for information risks. Keeping secure the information we hold, particularly sensitive personal patient data, is of the highest priority, and this principle will frame our approach to the implementation of the Digital Projects in the coming year.

The incoming General Data Protection Regulations (GDPR) have required we undertake a thorough review of the personal data we hold, how it is used and how we communicate our approach to the public. Although the information we hold on our Register is exempt these regulations we have made considerable progress in identifying the data we hold that does fall within the scope of GDPR. We are confident that we will achieve a compliant position ahead of the implementation date of 25 May 2018.

There were no data losses within the last year and we continue to work hard to ensure that remains the case.

Whistleblowing arrangements

Our Public Interest Disclosure (Whistleblowing) policy sets out how any concerns can be raised by staff and what action would be taken. It aims to reassure staff that they should raise concerns openly and that

⁶ Available at www.gov.uk/government/publications/review-of-quality-assurance-of-government-models.

there will be no repercussions for them if they raise concerns in good faith. The policy has been communicated to staff through line management and our intranet.

As well as line management and HR channels, staff can approach the NAO hotline and Public Concern at Work for advice.

During the year, there have been no concerns raised under whistleblowing arrangements. Staff raise issues and make suggestions as part of day to day working in line with our culture.

Internal incidents

Our Executive maintains an internal incident procedure, which ensures that any process failures are quickly and thoroughly investigated. This allows SMT to learn lessons and correct potential procedural failures. The system and associated documentation was reviewed during the year to bring it in line with our other documentation and overall brand.

Overall conclusion

We have embedded improved risk management processes and I am assured that a robust governance and assurance framework is in place, that our risks are managed proportionately, and that appropriate financial controls are in effect. My assessment has been informed also by internal audit reviews during the year of our approach to securing data and preventing data loss, governance around our risk management processes, our approach to meeting the General Data protection regulations that come in to force on 25 May 2018 and finally the robustness of our financial control regime.

I have noted the moderate annual opinion of our internal audit which relate to risk management, governance and control. As we look to the future, I have full confidence that we will continue to develop assurance mechanisms, while improving the quality of our work and seeking to provide best value for public finances and patients.



Peter Thompson
Chief Executive
Accounting Officer

27 June 2018

Remuneration report (Audited)

Audit

Specific areas of the Remuneration report are audited by NAO, the HFEA's external auditors. These sections cover salary and pension data in the tables, non-cash benefits and amounts payable to third parties for services of senior staff.

Reward systems and approval mechanisms for staff

Our remuneration recommendations are based on the Civil Service pay guidance issued annually by HM Treasury.

Pay awards were made to eligible staff in 2017/18 in accordance with the Government limit of 1% of the total pay-bill. This is the same as the previous year.

Pay levels are reviewed annually through the Remuneration Committee, which has specific responsibility to monitor overall levels of remuneration and to approve the remuneration of the Chief Executive and the directors (see below).

Duration of contracts, notice periods and termination payments

Members of staff in bands one (assistant grade) and two (officers) must provide six weeks' notice of termination of their contracts. Members of staff in band three (managers) and above must provide three months' notice of termination of their contracts. The HFEA has a statutory duty to provide notice to staff of between one week and twelve weeks' notice depending on continuous service in line with the Employment Rights Act 1996.

Termination payments are made only in appropriate circumstances. In cases where gross misconduct has occurred, no termination payments are made.

Authority members

The remuneration levels of Authority members are set nationally and are summarised in the table below. Revisions are made in accordance with the agreement on the pay framework for ALB chairs and non-executive directors, announced in March 2006. We implement the revisions when instructed.

No pension contributions or bonuses were paid on behalf of any Authority member in 2017/18.

Appeals Committee

The Appeals Committee Chair receives a fee of £269 per day. The Deputy Chair receives a fee of £208 per day and the committee's members receive a fee of £190 per day. No pension contributions were paid on behalf of any Appeals Committee member.

The Chair of the Appeals Committee, Mr Peter Freeman CBE, QC Hon was appointed on 13 March 2017 and received a payment of £3,489.63 in the period ended 31 March 2018. No payment was made to the Deputy Chair of the Appeals Committee, Ms Julie Matheson, during the year. Appeals Committee members Samuel Stein and Peter North received £1,327.69 each. No payments were made to the other Appeals Committee members Dr Elizabeth Haxby, Alice Robertson-Pickard or David Kyle.

End of service

Staff can access their Civil Service pension at different times, depending on the scheme they are in. The normal pension age for those in the classic/premium scheme is 60, for those in the Nuvos scheme it is 65 and for those in the Alpha scheme it is the later of 65 or the state pension age. However, some staff may wish to work beyond these ages.

Early termination, other than for misconduct, would result in the individual receiving compensation as set out in the Civil Service Compensation Scheme.

Trade Unions

Under the Facility Time Publication Requirements Regulations of 2017, the HFEA are required to disclose the number of staff, costs and time spent on facility time by an employee who is a relevant union official if it meets certain criteria.

The HFEA does not recognise any trade union and therefore does not employ any staff members who allocates their time on trade union activities.

Remuneration and benefits to Authority members for the year ending 31 March 2018 (Audited)

Name	Salary range £000s	Expenses (to nearest £100) ⁷ £	Total £000s	Salary range £000s	Expenses (to nearest £100) £	Total £000s
	2017/18	2017/18	2017/18	2016/17	2016/17	2016/17
Sally Cheshire (Chair)	45-50	14,500	60-65	45-50	19,000	65-70
Andy Greenfield	5-10	900	5-10	5-10	1,900	5-10
David Archard (Deputy Chair) *	N/a	N/a	N/a	5-10	4,500	10-15
Rebekah Dundas*	N/a	N/a	N/a	10-15	4,500	15-20
Lee Rayfield	5-10	1,300	5-10	5-10	700	5-10
Kate Brian	5-10	100	5-10	5-10	0	5-10
Anthony Rutherford	5-10	500	5-10	5-10	200	5-10
Yacoub Khalaf	5-10	0	5-10	5-10	100	5-10
Margaret Gilmore	5-10	1,900	10-15	5-10	2,100	10-15
Anita Bharucha	10-15	800	10-15	5-10	1,400	10-15
Anne Lampe	5-10	3,700	10-15	5-10	3,300	10-15
Ruth Wilde	5-10	1,000	5-10	5-10	700	5-10
Bobbie Farsides	5-10	600	5-10	0-5	200	0-5

*Members who left but have been included for comparative figures.

Benefits in kind

The monetary value of benefits in kind covers any benefits provided by us and treated by HMRC as a taxable emolument. We have agreed a PAYE settlement agreement (PSA) with HMRC in regard to taxable emoluments of Authority members and some of our compliance staff, for the travel, accommodation, meals and subsistence for which we pay the tax and national insurance due.

Information regarding travel and subsistence claimed by Authority members and senior management is published on our website www.hfea.gov.uk.

Chief Executive and directors

The Chief Executive's pay is set in accordance with the recommendation of the Chair, subject to the review of the Remuneration Committee and with the agreement of the DHSC. This is in accordance with

⁷ These expenses are shown net of tax and national insurance

the pay framework for very senior managers (VSM) in ALBs, informed by the Senior Staff Salaries Review Board.

Remuneration of the directors must be approved by the Remuneration Committee and is based on proposals received from the Chief Executive, in accordance with the VSM pay framework.

The members of the Remuneration Committee during the year were Sally Cheshire (Chair), Margaret Gilmore and Anita Bharucha.

Remuneration and pension benefits of the senior management team (Audited)										
Name	Salary (£'000)		Bonus payments (£'000s)		Benefits in kind (to nearest £100)		Pension benefits ⁸ (£'000s)		Total (£'000s)	
	2017/18	2016/17	2017/18	2016/17	2017/18	2016/17	2017/18	2016/17	2017/18	2016/17
Peter Thompson	135-140	135-140	0	0	0	0	(8)	28	130-135	165-170
Nick Jones	95-100	95-100	0-5	0	0	0	39	38	135-140	135-140
Richard Sydee	90-95	35-40 (Fte 90-95)	0	0	0	0	36	15	125-130	50-55 (Fte 90-95)
Juliet Tizzard (resigned 1 January 2018)	65-70 (Fte 90-95)	90-95	0	0-5	0	0	23	40	90-95	130-135
Clare Ettinghausen (appointed 29 January 2018)	15-20 (Fte 90-95)	N/a	0	N/a	0	N/a	6	N/a	20-25	N/a
Sue Gallone ⁹	N/a	10-15	N/a	N/a	N/a	N/a	N/a	N/a	N/a	10-15

⁸ The value of pension benefits accrued during the year is calculated as (the real increase in pension multiplied by 20) plus (the real increase in any lump sum) less (the contributions made by the individual). The real increases exclude increases due to inflation or any increase or decreases due to a transfer of pension rights.

⁹ Sue Gallone included for comparative information only

Median pay and multiples (Audited)

	2017/18	2016/17
Band of highest paid director's gross salary only	£135k-£140k	£135k-£140k
Median total remuneration	£36,724	£37,127
Ratio – gross salary only	3.74	3.70

The FReM reporting requirements require public sector bodies to disclose the relationship between the total remuneration of the highest-paid director in their organisation and the median remuneration of the organisation's workforce.

The banded remuneration of the highest-paid director in the financial year 2017/18 was £135,000-140,000 (2016/17 £135,000-£140,000). This was 3.74 times (2016/17, 3.70) the median remuneration of the workforce, which was £36,724 (2016/17 £37,127). In 2017/18, 0 (2016/17, 0) employees received remuneration in excess of the highest-paid director. Remuneration ranged £24,000 to £140,000.

Total remuneration includes salary, non-consolidated performance-related pay and benefits-in-kind. It does not include severance payments, employer pension contributions and the cash equivalent transfer value of pensions. We are a London-based small expert organisation whose work requires scientific and other professional or graduate-level skills. Consequently, median pay remains higher than that for a number of other public sector bodies.

Staff report (Audited)

The HFEA has a headcount of 64 staff members excluding Authority members and including the SMT as at 31 March 2018. Below is a breakdown of staff costs and an analysis of directly employed staff.

	Permanently employed staff	Members	2017/18 Total	2016/17 Total
	£	£	£	£
Salaries and wages	3,266,233	132,191	3,398,424	2,985,795
Social security costs	275,008	6,161	281,169	270,299
Other pension costs	552,175	0	552,175	560,182
Net staff costs	4,093,416	138,352	4,231,768	3,816,276
Less recoveries in respect of outward secondments	(96,906)	0	(96,906)	(25,957)
Total Net Staff costs¹⁰	3,996,510	138,352	4,134,862	3,790,319

¹⁰ Staff costs are higher this year due to the need to use Agency staff to cover certain vacancies and to provide support for work needed on Data cleansing. (Agency staff cost of £466,603).

Exit packages (Audited)

Exit package cost band (including any special payment element)	Number of compulsory redundancies	Cost of compulsory redundancies	Number of other departures agreed	Cost of other departures	Total cost of exit packages
		£'000s		£'000s	£000s
Less than £10,000	0	0	0	0	0
£10,000-£25,000	0	0	0	0	0
£25,001-£50,000	0	0	4	£153	£153
£50,001-£100,000	0	0	0	£ 0	£ 0
£101,000-£150,000	0	0	1	£105	£105
£150,001-£200,000	0	0	0	0	0
>£200,000	0	0	0	0	0
Totals	0	0	5	£258	£258

Redundancy and other departure costs have been paid in accordance with the provisions of the Civil Service Pension Scheme. Exit costs in this note are accounted for in full in the year of departure. Where the HFEA has agreed early retirements, the additional costs are met by the HFEA and not by the Civil Service pensions scheme. Ill-health retirement costs are met by the Civil Service pensions scheme and are not included in the table. There were no exit packages paid in 2016/17.

Average number of persons permanently employed and outwardly seconded (Audited)

	Permanently employed	Seconded	2017/18 Total	2016/17 Total ¹¹
SCS ¹²	4	0	4	3
Other	56	1	57	61
Total	60	1	61	64

Sickness and absences

Our sickness absence aim is to lose no more than 3% of time in staff sickness absence and in 2017/18 we achieved 1.4% (2016/17 2.1%). This compares favourably with the public-sector sickness absence rate average which is 2.9% (Office for National Statistics (ONS) 2016).

¹¹ These numbers have been rounded.

¹² Includes the Shared Director

Off-payroll assurance statement

We have not entered into any off-payroll engagements during the 2017/18 financial year (2016/17 nil).

Consultancy

Our expenditure on Consultancy is £270,536 as listed within the financial statements on page 50 and relates to legal costs incurred.

Remuneration and pension entitlements

The Government financial reporting manual (FReM) requires us to provide information on the remuneration and pension rights of the named individuals who are our most senior managers.

The following table provides details of the remuneration and pensions of the Chief Executive and directors. These figures are subject to audit.

The pension entitlements of the most senior managers in the HFEA (Audited)

Name and position	Total accrued pension at age 65 as at 31 March 2018	Real increase in pension and related lump sum at age 65	CETV at 31 March 2017	CETV at 31 March 2018	Real increase in CETV as funded by HFEA
	Band	Band			
	£'000s	£'000s	£'000s	£'000s	£'000s
Peter Thompson Chief Executive	50-55	0-2.5	897	950	(9)
Richard Sydee Director of Finance and Resources	0-5	0-2.5	8	29	14
Nick Jones Director of Compliance and Information	15-20	0-2.5	205	240	21
Clare Ettinghausen Director of Strategy and Corporate Affairs (appointed 29 January 2018)	0-5	0-2.5	0	4	2
Juliet Tizzard Director of Strategy and Corporate Affairs (resigned 1 January 2018)	15-20	0-2.5	181	203	8

All senior managers listed are employed on a permanent basis and are covered by the terms of the Principal Civil Service Pension Scheme.

Definitions

'Salary' includes gross salary, performance pay or bonuses and any other allowance that is subject to UK taxation.

'Total remuneration' includes salary, non-consolidated performance-related pay and benefits in kind as well as severance payments. It does not include employer pension contributions and the cash equivalent transfer value of pensions.

'Benefits in kind' covers the monetary value of any benefits provided by the employer.

This report is based on payments made by us and thus recorded in these accounts.

Civil Service Pensions

The Principal Civil Service Pension Scheme (PCSPS) and the Civil Servant and Other Pension Scheme (CSOPS) – known as “Alpha” are unfunded multi-employer defined benefit schemes but the HFEA is unable to identify its share of the underlying assets and liabilities.

The scheme actuary valued the PCSPS as at 31 March 2012. You can find details in the resource accounts of the Cabinet Office: Civil Superannuation at

<https://www.civilservicepensionscheme.org.uk/about-us/resource-accounts/>

For 2017/18, employers’ contributions of £547,170 were payable to the PCSPS (2016/17 £560,182) at one of the four rates in the range 20.0% to 24.5% of pensionable earnings, based on salary bands.

The Scheme Actuary reviews employer contributions usually every four years following a full scheme valuation. The contribution rates are set to meet the cost of the benefits accruing during 2017/18 to be paid when the member retires and not the benefits paid during the period to existing pensioners.

Employees can opt to open a partnership pension account, a stakeholder pension with employer contribution. Employers’ contributions of £10,248 were paid to one or more of the panel of three appointed stakeholder pension providers. Employer contributions are age-related and ranged from 8% to 14.75%.

Employers also match employee contributions up to 3% of pensionable earnings. In addition, employer contributions of £376, 0.5% (previously 0.8%) of pensionable pay, were payable to the PCSPS to cover the cost of the future provision of lump sum benefits on death in service or ill health retirement of these employees.

Further details about the Civil Service pension arrangements can be found at the website www.civilservicepensionscheme.org.uk.

A Cash Equivalent Transfer Value (CETV) is the actuarially assessed capitalised value of the pension scheme benefits accrued by a member at a particular point in time. The benefits valued are the member’s accrued benefits and any contingent spouse’s pension payable from the scheme. A CETV is a payment made by a pension scheme or arrangement to secure pension benefits in another pension scheme or arrangement when the member leaves a scheme and chooses to transfer the benefits accrued in their former scheme. The pension figures shown relate to the benefits that the individual has accrued as a consequence of their total membership of the pension scheme, not just their service in a senior capacity to which disclosure applies.

The figures include the value of any pension benefit in another scheme or arrangement which the member has transferred to the Civil Service pension arrangements. They also include any additional pension benefit accrued to the member as a result of their buying additional pension benefits at their own cost. CETVs are worked out in accordance with ‘The occupational pension schemes (transfer values) (amendment) regulations 2008’ and do not take account of any actual or potential reduction to benefits resulting from lifetime allowance tax which may be due when pension benefits are taken.

Real increase in CETV

This reflects the increase in CETV that is funded by the employer. It does not include the increase in accrued pension due to inflation, contributions paid by the employee (including the value of any benefits transferred from another pension scheme or arrangement) and uses common market valuation factors for the start and end of the period.

Audit

All tabular data contained in this remuneration report together with employer pension contributions are subject to audit.



Peter Thompson
Chief Executive
Accounting Officer

27 June 2018

Parliamentary accountability and audit report

Accountability

Fees and charges (Audited)

Our licence fees are set to recover the full cost incurred in the granting of licences and regulation. The table below shows the income from the sector for licensing activities and the associated costs of licensing.

	March 2017/18	March 2016/17
	£	£
Income from regulatory activity ¹³	5,310,861	5,322,910
Costs allocated to regulatory activity	(4,946,765)	(4,455,488)
Surplus/(Deficit)	364,096	867,422

We confirm that we have complied with the cost allocation and charging requirements as set out in HM Treasury's guidance.

Licence fee income is derived from a fixed fee charged on the number of treatment cycles that are undertaken across the sector in the financial year. In some years it has proven difficult to predict the number of cycles accurately and this was true in 2017/18 and accounts for the surplus generated. In response this year we have developed a forecast model with the aim of more accurately predicting treatment cycles and income any given period. Early signs are that the model is working well with 99.8% accuracy which should improve our ability to set fees at an appropriate level to cover our costs.

In addition, there are elements of our work that do not relate directly to the cost of regulating the sectors below. The DHSC accordingly contributes to the funding of these activities through the provision of grant-in-aid.

Losses and special payments (Audited)

Losses and special payments are items that Parliament would not have contemplated when it agreed funds for health service or passed legislation. By their nature they are items that should not arise and are therefore subject to special controls. The HFEA had no losses or special payments in 2017/18.

Remote contingent liabilities (Audited)

There are no remote contingent liabilities this year.

¹³ Income includes a portion of interest received

THE CERTIFICATE AND REPORT OF THE COMPTROLLER AND AUDITOR GENERAL TO THE HOUSES OF PARLIAMENT

Opinion on financial statements

I certify that I have audited the financial statements of Human Fertilisation and Embryology Authority for the year ended 31 March 2018 under the Human Fertilisation and Embryology Act 1990. The financial statements comprise: the Statements of Comprehensive Net Expenditure, Financial Position, Cash Flows, Changes in Taxpayers' Equity; and the related notes, including the significant accounting policies. These financial statements have been prepared under the accounting policies set out within them. I have also audited the information in the Accountability Report that is described in that report as having been audited.

In my opinion:

- the financial statements give a true and fair view of the state of the Human Fertilisation and Embryology Authority affairs as at 31 March 2018 and of net expenditure for the year then ended; and
- the financial statements have been properly prepared in accordance with the Human Fertilisation and Embryology Act 1990 and Secretary of State directions issued thereunder.

Opinion on regularity

In my opinion, in all material respects the income and expenditure recorded in the financial statements have been applied to the purposes intended by Parliament and the financial transactions recorded in the financial statements conform to the authorities which govern them.

Basis of opinions

I conducted my audit in accordance with International Standards on Auditing (ISAs) (UK) and Practice Note 10 'Audit of Financial Statements of Public Sector Entities in the United Kingdom. My responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of my certificate. Those standards require me and my staff to comply with the Financial Reporting Council's Revised Ethical Standard 2016. I am independent of the Human Fertilisation and Embryology Authority in accordance with the ethical requirements that are relevant to my audit and the financial statements in the UK. My staff and I have fulfilled our other ethical responsibilities in accordance with these requirements. I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my opinion.

Responsibilities of the Authority and Accounting Officer for the financial statements

As explained more fully in the Statement of Accounting Officer's Responsibilities, the Authority and the Accounting Officer are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view.

Auditor's responsibilities for the audit of the financial statements

My responsibility is to audit, certify and report on the financial statements in accordance with the Human Fertilisation and Embryology Act 1990.

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK), I exercise professional judgment and maintain professional scepticism throughout the audit. I also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for my opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Human Fertilisation and Embryology Authority internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Human Fertilisation and Embryology Authority ability to continue as a going concern. If I conclude that a material uncertainty exists, I am required to draw attention in my auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify my opinion. My conclusions are based on the audit evidence obtained up to the date of my auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

In addition, I am required to obtain evidence sufficient to give reasonable assurance that the [income and expenditure/receipts and payments] reported in the financial statements have been applied to the purposes intended by Parliament and the financial transactions conform to the authorities which govern them.

I communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that I identify during my audit.

In addition, I am required to obtain evidence sufficient to give reasonable assurance that the [income and expenditure reported in the financial statements have been applied to the purposes intended by Parliament and the financial transactions conform to the authorities which govern them.

Other Information

The Board and the Accounting Officer are responsible for the other information. The other information comprises information included in the annual report, other than the parts of the Accountability Report described in that report as having been audited, the financial statements and my auditor's report thereon. My opinion on the financial statements does not cover the other information and I do not express any form of assurance conclusion thereon. In connection with my audit of the financial statements, my responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or my knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work I have performed, I conclude that there is a material misstatement of this other information, I am required to report that fact. I have nothing to report in this regard.

Opinion on other matters

In my opinion:

- the parts of the Accountability Report to be audited have been properly prepared in accordance with Secretary of State directions made under the Human Fertilisation and Embryology Act 1990;
- in the light of the knowledge and understanding of its environment obtained in the course of the audit, I have not identified any material misstatements in the Performance Report or the Accountability Report; and
- the information given in Performance Report and Accountability Report for the financial year for which the financial statements are prepared is consistent with the financial statements.

Matters on which I report by exception

I have nothing to report in respect of the following matters which I report to you if, in my opinion:

- adequate accounting records have not been kept or returns adequate for my audit have not been received from branches not visited by my staff; or
- the financial statements and the parts of the Accountability Report to be audited are not in agreement with the accounting records and returns; or
- I have not received all of the information and explanations I require for my audit; or
- the Governance Statement does not reflect compliance with HM Treasury's guidance.

Report

I have no observations to make on these financial statements.

Sir Amyas C E Morse
Comptroller and Auditor General

Date 28 June 2018

National Audit Office
157-197 Buckingham Palace Road
Victoria
London
SW1W 9SP

Financial statements

Statement of comprehensive net expenditure for the year ended 31 March 2018

	NOTE	March 2018 £	March 2017 £
Income			
Income from activities	4	5,305,022	5,322,910
Other operating income	4	97,306	25,967
		5,402,328	5,348,877
Expenditure			
Staff costs	3	4,231,768	3,816,276
Purchase of goods and services	3	324,221	438,794
Depreciation and impairment charges	3	227,093	44,888
Loss on disposal of assets	3	0	780
Other operating expenditure	3	1,118,551	1,112,448
		5,901,633	5,413,186
Net operating expenditure		(499,305)	(64,309)
Finance income	4	5,839	3,695
Finance expense		0	0
Net expenditure for the year		(493,466)	(60,614)
Taxation		(1,142)	(710)
Net comprehensive (expenditure) for the year		(494,608)	(61,324)

The notes on pages 46 to 60 form part of these accounts.

Statement of financial position as at 31 March 2018

		31 March 2018	31 March 2017
	NOTE	£	£
Non-current assets:			
Property, information technology and office equipment	5	39,162	68,946
Intangible assets	6	<u>1,288,319</u>	<u>1,010,954</u>
Total non-current assets		1,327,481	1,079,900
Current assets:			
Trade and other receivables	8	956,890	1,175,968
Cash and cash equivalents	9	<u>3,227,729</u>	<u>2,352,904</u>
Total current assets		4,184,619	3,528,872
Total assets		<u>5,512,100</u>	<u>4,608,772</u>
Current liabilities			
Trade and other payables	10	(631,443)	(573,507)
Provisions	11	<u>(25,000)</u>	<u>(118,000)</u>
Total current liabilities		<u>(656,443)</u>	<u>(691,507)</u>
Non-current assets less net current liabilities		<u>4,855,657</u>	<u>3,917,265</u>
FINANCED BY:			
Taxpayers' equity			
I&E reserve		<u>(4,855,657)</u>	<u>(3,917,265)</u>
Total taxpayers' equity:		<u>(4,855,657)</u>	<u>(3,917,265)</u>

The notes on pages 46 to 60 form part of these accounts.

The financial statements on pages 42 to 45 were approved by the board on 19 June 2018 and signed on its behalf by:



Peter Thompson
Chief Executive

Date: 27 June 2018

Statement of cash flows for the year ended 31 March 2018

	NOTE	March 2018 £	March 2017 £
Cash flows from operating activities			
Net operating surplus/(deficit) after interest		(493,466)	(60,614)
Depreciation and amortisation	3	227,093	44,888
(Increase)/decrease in trade and other receivables	8	219,078	(418,962)
Increase/(decrease) in trade and other payables	10	57,936	150,893
Loss on disposals of non-current assets	3	0	780
Taxation		(1,142)	(710)
Use of provisions	11	(93,000)	19,786
Net cash inflow/(outflow) from operating activities		<u>(83,501)</u>	<u>(263,939)</u>
Cash flows from investing activities			
Purchase of property, plant and equipment	5	0	(13,865)
Purchase of intangible assets	6	(474,674)	(560,064)
Proceeds of disposal of property, plant and equipment		0	512
Net cash inflow/(outflow) from investing activities		<u>(474,674)</u>	<u>(573,417)</u>
Cash flows from financing activities			
Grants from sponsoring department		1,433,000	1,033,000
Net cash inflow/(outflow) from financing activities		<u>1,433,000</u>	<u>1,033,000</u>
Net financing		<u>874,825</u>	<u>195,644</u>
Net increase/(decrease) in cash and cash equivalents in the period	9	874,825	195,644
Cash and cash equivalents at the beginning of the period	9	2,352,904	2,157,260
Cash and cash equivalents at the end of the period		<u>3,227,729</u>	<u>2,352,904</u>

As at 31 March 2018 there were no fixed asset accruals (2016/17 £Nil).

The notes on pages 46 to 60 form part of these accounts

Statement of changes in taxpayers' equity For the year ended 31 March 2018

	Total I&E reserve
	£
Balance at 1 April 2016	2,945,589
Changes in taxpayers' equity for March 2017	
Grant from Department of Health and Social Care	1,033,000
Comprehensive income/(expenditure) for the year	(61,324)
Balance at 31 March 2017	3,917,265
Changes in taxpayers' equity for the year ended 31 March 2018	
Grant from Department of Health and Social Care	1,433,000
Comprehensive income/(expenditure) for the year	(494,608)
Balance at 31 March 2018	4,855,657

The notes on pages 46 to 60 form part of these accounts

Notes to the accounts

1. Statement of accounting policies

The HFEA accounts are prepared in accordance with the provisions of the Human Fertilisation and Embryology Act 1990 (as amended) and an Accounts Direction issued by the Secretary of State for Health in June 2007.

The accounts are prepared in accordance with the accounting and disclosure requirements given in HM Treasury's Financial Reporting Manual (FReM), insofar as these are appropriate to the HFEA and are in force for the financial year for which the statements are prepared. The accounting policies contained in the FReM apply International Financial Reporting Standards (IFRS) as adapted or interpreted for the public sector context.

Where the FReM permits a choice of accounting policy, the accounting policy which is judged to be the most appropriate to the particular circumstance of the HFEA for the purpose of giving a true and fair view has been selected.

The particular policies adopted by the HFEA are described below. They have been applied consistently in dealing with items that are considered material to the accounts.

1.1 Accounting convention

These financial statements are prepared under the historical cost convention.

1.2 Non-current assets

Non-current assets include property, information technology, and office equipment together with intangible assets which relate to constructed software and software licenses. Only items, or groups of related items, costing £5,000 or more are capitalised. Those costing less are treated as revenue expenditure.

All property, plant and equipment and intangible assets held by the HFEA at 31 March 2018 are carried in the statement of financial position at depreciated (property, plant and equipment) or amortised (intangible assets) historical cost. The depreciated or amortised historical cost is used as a proxy for fair value, for the classes of assets listed below, since the useful life over which the asset class is depreciated or amortised is considered to be a realistic reflection of the consumption of that asset class.

1.3 Critical accounting judgements and key sources of estimation uncertainty

In the application of the HFEA accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources.

The following are critical judgements that have been made in the process of applying HFEA's accounting policies.

Provisions and accruals have been based upon information provided by staff

Deferred income estimates are based upon licensing information provided by the Inspectorate teams.

1.4 Depreciation and amortisation

Depreciation is provided on all non-current assets on a monthly basis from the date of acquisition at rates calculated to write off the cost of each asset evenly over its expected useful life.

Expected useful lives are as follows:

Information technology	4 years
Office equipment	5 years
Furniture, fixtures and fittings	5 years

Amortisation is provided on intangible non-current assets (which comprise constructed software and software licences) on a monthly basis at a rate calculated to write off the cost of each intangible asset over its expected useful life. The expected useful life of this software is four years.

1.5 Grant-in-aid

Grant-in-aid received is used to finance activities and expenditure which supports the statutory and other objectives of the HFEA and is treated as financing and credited to the I&E reserve, because it is regarded as contributions from a controlling party.

1.6 Operating income

Licence fee income is recognised at the time of treatment date.

An estimate of the income for treatments provided by the clinics, but not reported to the HFEA, at 31 March 2018, is accrued. This is calculated by clinics in a report from the automated billing system (ABS) based on the typical delay between the clinic providing the treatment to the patient and reporting the treatment to the HFEA and the clinic's recently reported monthly treatment numbers.

Deferred income is recognised in respect of income for annual licence fees.

1.7 Operating leases

Operating leases are charged to the accounts on a straight line basis over the lease term.

1.8 Pensions

Past and present employees are covered by the provisions of the Principal Civil Service Pension Scheme (PCSPS). The defined benefit elements of the scheme are unfunded and are non-contributory except in respect of dependents' benefits. The HFEA recognises the expected cost of these elements on a systematic and rational basis over the period during which it benefits from employees' services by payment to the PCSPS of amounts calculated on an accruing basis. Liability for payment of future benefits is a charge on the PCSPS. In respect of the defined contribution elements of the scheme, the HFEA recognises the contributions payable for the year. Further information in respect of Civil Service Pensions is provided in the remuneration report.

1.9 Cash

Cash is cash in hand and deposits with any financial institution repayable without penalty on notice of not more than 24 hours.

1.10 Financial instruments

Financial assets and financial liabilities arise from the Authority's normal operational activities and are recognised in accordance with standard accruals accounting principles.

The HFEA's financial assets comprise cash at bank and in hand, license fee debtors, balances with central Government bodies, and other debtors. The HFEA's financial liabilities comprise trade creditors and other creditors.

The fair values of financial assets and liabilities are deemed to be their book values, unless there is appropriate cause to apply an alternative basis of valuation.

The HFEA has not entered into any transactions involving derivatives.

1.11 Provisions

Provisions are recognised when the HFEA has a present legal or constructive obligation as a result of a past event, it is probable that the HFEA will be required to settle the obligation, and a reliable estimate can be made of the obligation. The amount recognised as a provision is the best estimate of expenditure required to settle the obligation at the end of the reporting period, taking into account the risks and uncertainties.

1.12. IFRSs, amendments and interpretations in issue but not yet effective

The Treasury FReM does not require the following standards and interpretations to be applied in 2017/18. The application of the standards as revised would not have a material impact on the accounts in 2017/18, were they applied in that year.

IFRS 9 Financial Instruments - we hold simple financial assets in the form of trade receivables, therefore the implementation of this standard will have no material impact. The standard is effective from 1 January 2018.

IFRS 15 Revenue from contracts with customers - managements' assessment of each income stream against the five-step model has confirmed that the implementation of this standard has an insignificant impact. This standard is effective from 1 January 2018.

IFRS 16 Leases replaces IAS 17 and is effective for the public sector from 1 January 2019. The new standard amends the accounting for lessees, removing the distinction between recognising an operating lease (off balance sheet) and a finance lease (on balance sheet). The new standard requires recognition of most leases which last more than 12 months to be recognised on balance sheet. The new standard will therefore impact on the Authority's operating leases which are disclosed in Note 13.

2. Operating segments

Under the definition of IFRS 8 the HFEA is a single operating segment as the UK's independent regulator of treatment using eggs and sperm, and of treatment and research involving human embryos, setting standards for, and the issue of licences to, centres together with the provision of information for the public and determining the policy framework for fertility issues.

	Note	March 2018 £	March 2017 £
3. Operating expenditure			
3.1 Staff costs			
Permanently employed staff costs		3,626,813	3,527,434
Members' allowances		138,352	144,058
Agency and other temporary costs		466,603	144,784
	3(a)	<u>4,231,768</u>	<u>3,816,276</u>
3.2 Purchase of goods and services			
Professional & administrative fees	(b)	270,536	374,318
Auditors' remuneration and expenses	(c)	53,685	64,476
		<u>324,221</u>	<u>438,794</u>
3.3 Depreciation and impairment charges			
Depreciation & amortisation	5,6	227,093	44,888
Loss on disposal of assets		0	780
		<u>227,093</u>	<u>45,668</u>
3.4 Other operating expenses			
Rentals under operating leases		361,540	329,763
Running costs		449,875	428,906
Other staff costs		282,136	235,779
Provision provided in year	11	25,000	118,000
		<u>1,118,551</u>	<u>1,112,448</u>
Total		<u>5,901,633</u>	<u>5,413,186</u>

Notes

b) Professional and administrative fees are legal costs incurred this year.

c) Audit expenditure is as follows:

	March 2018 £	March 2017 £
External audit	28,000	28,000
Internal audit	25,685	36,476
	<u>53,685</u>	<u>64,476</u>

External audit expenditure is the accrued fee for the NAO for 12 months. The internal audit costs relate to audits carried out in 2017-18 .

3a. Staff costs

	March 2018				March 2017
	Total	Permanently Employed Staff	Members	Temporary staff	Total
	£	£	£	£	£
Wages and salaries	3,398,424	2,799,630	132,191	466,603	2,985,795
Social security costs	281,169	275,008	6,161	0	270,299
Other pension costs	552,175	552,175	0	0	560,182
Staff costs	4,231,768	3,626,813	138,352	466,603	3,816,276
Less recoveries in respect of outward secondments	(96,906)	(96,906)	0	0	(25,957)
Total Net staff costs	4,134,862	3,529,907	138,352	466,603	3,790,319

As set out in note 1.8, further information in respect of Civil Service Pensions is provided in the remuneration report on pages 26 to 35.

Average number of staff employed

The average numbers of persons employed during the period were as follows

	Permanent staff	March 2018 Seconded staff	March 2018 Total	March 2017 Total
SCS	4	0	4	3
Other	56	1	57	61
Total	<u>60</u>	<u>1</u>	<u>61</u>	<u>64</u>

The average number of FTE staff directly employed for the period ended 31 March 2018 was 61 (2016/17, 64). The other staff member is seconded to the Home Office.

Temporary staff costs of £466,603 are included within salaries and wages. Below are the average number of temp staff utilised in the 2017/18 financial year

<u>18</u>	<u>11</u>
-----------	-----------

4. Income

Gross income is made up of licence fee and other incomes which are recorded on an accruals basis.

Analysis of income

	31 March 2018 £	31 March 2017 £
Licence fee income	5,305,022	5,322,910
Other income-interest	5,839	3,695
Other operating income	97,306	25,967
Total income for the year	<u>5,408,167</u>	<u>5,352,572</u>

Other operating income includes income from seconded staff to the HTA

5. Property, plant and equipment

March 2018	Information technology £	Office equipment £	Furniture & fittings £	Total £
Cost or valuation:				
At 1 April 2017	199,813	17,470	0	217,283
Additions purchased	0	0	0	0
Disposals	(46,888)	(8,980)	0	(55,868)
At 31 March 2018	152,925	8,490	0	161,415
Depreciation				
At 1 April 2017	136,099	12,238	0	148,337
Charged during the year	27,073	2,711	0	29,784
Disposals	(46,888)	(8,980)	0	(55,868)
At 31 March 2018	116,284	5,969	0	122,253
Carrying value at 31 March 2018	36,641	2,521	0	39,162
Carrying value at 31 March 2017	63,714	5,232	0	68,946
Asset financing:				
Owned	36,641	2,521	0	39,162
Total at 31 March 2018	36,641	2,521	0	39,162
March 2017				
Cost or valuation:				
At 1 April 2016	405,786	20,746	21,029	447,561
Additions purchased	10,345	3,520	0	13,865
Disposals	(216,318)	(6,796)	(21,029)	(244,143)
At 31 March 2017	199,813	17,470	0	217,283
Depreciation				
At 1 April 2016	326,122	16,180	20,230	362,532
Charged during the year	25,778	2,856	22	28,656
Disposals	(215,801)	(6,798)	(20,252)	(242,851)
At 31 March 2017	136,099	12,238	0	148,337
Carrying value at 31 March 2017	63,714	5,232	0	68,946
Carrying value at 31 March 2016	79,664	4,566	799	85,029
Asset financing:				
Owned	63,714	5,232	0	68,946
Total at 31 March 2017	63,714	5,232	0	68,946

6. Intangible assets

	Software licenses	Constructed software ¹	Asset under construction development expenditure	Total
	£	£	£	£
March 2018				
Cost or valuation:				
At 1 April 2017	261,213	498,706	977,643	1,737,562
Additions purchased	0	0	474,674	474,674
Reclassification	0	977,643	(977,643)	0
Disposals	(2,532)	0	0	(2,532)
At 31 March 2018	258,681	1,476,349	474,674	2,209,704
Depreciation				
At 1 April 2017	227,902	498,706	0	726,608
Charged during the year	14,001	183,308	0	197,309
Disposals	(2,532)	0	0	(2,532)
At 31 March 2018	239,371	682,014	0	921,385
Carrying value at 31 March 2018	19,310	794,335	474,674	1,288,319
Carrying value at 31 March 2017	33,311	0	977,643	1,010,954
Asset financing:				
Owned	19,310	794,335	474,674	1,288,319
Total at 31 March 2018	19,310	794,335	474,674	1,288,319
March 2017				
Cost or valuation:				
At 1 April 2016	265,533	498,706	440,568	1,204,807
Additions purchased	22,989	0	537,075	560,064
Disposals	(27,309)	0	0	(27,309)
At 31 March 2017	261,213	498,706	977,643	1,737,562
Depreciation				
At 1 April 2016	238,979	498,706	0	737,685
Charged during the year	16,232	0	0	16,232
Disposals	(27,309)	0	0	(27,309)
At 31 March 2017	227,902	498,706	0	726,608
Carrying value at 31 March 2017	33,311	0	977,643	1,010,954
Carrying value at 31 March 2016	26,554	0	440,568	467,122
Asset financing:				
Owned	33,311	0	977,643	1,010,954
Total at 31 March 2017	33,311	0	977,643	1,010,954

¹Constructed software is the cost of HFEA's website, Choose-a-Fertility Clinic (CaFC) and the Clinic Portal which collectively were known as the Information for Quality Project that concluded in July 2017.

7. Financial instruments

IFRS 7 requires disclosure of the role financial instruments have had during the period in creating or changing the risks an entity faces when undertaking its activities. Financial instruments play a much more limited role in creating or changing risk than would be typical of the listed companies to which IFRS 7 mainly applies. The HFEA has no powers to borrow funds, and financial assets and liabilities are generated by day-to-day operational activities rather than being held to manage the risks facing the HFEA in undertaking its activities.

a) Liquidity risk

The majority of the HFEA's income comes from treatment fees. The fees are based on information provided directly from licenced clinics. This information is processed and returned to clinics in the form of invoices.

There are procedures in place to identify late and non-reporting of treatment cycles by clinics and also procedures for chasing up debts. The remaining main source of revenue is from Government grants made on a cash basis. Therefore, the HFEA is not exposed to significant liquidity risk.

b) Investments and interest rate risk

The HFEA follows an investment policy of placing any surplus funds on overnight deposit in an interest bearing bank account.

Gross interest income was 0.11% of the total revenues of the HFEA. Therefore, the HFEA has no significant exposure to interest rate risk.

c) Credit risk

The HFEA receives most of its income from the clinics it regulates. It operates a robust debt management policy and, where necessary, provides for the risk of particular debts not being discharged by the relevant party, therefore it is not exposed to significant credit risk.

d) Financial assets and liabilities

The only financial asset held at a variable rate was cash at bank of £3,227,729. As at 31 March 2018, none of the HFEA's financial liabilities were carried at a variable rate. The fair value of the financial assets and liabilities was equal to the book value.

e) Foreign currency risk

Consistent with previous accounting periods there were minimal foreign currency transactions conducted by the HFEA during the period ended 31 March 2018. There was therefore no significant foreign currency risk during the year.

8. Trade and other receivables

	31 March 2018	31 March 2017
	£	£
Analysis by type		
Trade receivables - licence fee debtors	244,298	360,023
Prepayments and accrued income	680,874	729,294
Other receivables	31,718	86,651
Total	<u>956,890</u>	<u>1,175,968</u>

Prepayments and accrued income include calculations of the fees due to be invoiced to clinics after the date of the statement of financial position in respect of chargeable treatments undertaken before that date.

All debts were due for settlement within one year of the date of the statement of financial position. No provision for bad or doubtful debts has been made as all debts are anticipated to be recoverable.

9. Cash and cash equivalents

	31 March 2018
	£
Balance at 31 March 2016	2,157,260
Net change in cash	195,644
Balance at 31 March 2017	<u>2,352,904</u>
Net change in cash	874,825
Balance at 31 March 2018	<u><u>3,227,729</u></u>

£2,732,738 of the balance at 31 March 2018 was held with the Government Banking Services (£1,995,397 in 2016/17). The remaining balance was held at commercial banks.

No cash equivalents were held during the year.

10. Trade payables and other current liabilities

	31 March 2018 £	31 March 2017 £
Analysis by type		
Trade payables	63,379	260,941
Accruals and deferred income	552,545	305,198
Other payables	15,519	7,368
Total	<u>631,443</u>	<u>573,507</u>

All creditors were due for settlement within one year of the balance sheet date.

11. Provisions

	Legal costs	Early retirement and reorganisation costs	2017/18 Totals	2016/17 Totals
	£	£	£	
Balance at 1 April 2017	0	118,000	118,000	98,214
Provided in period	25,000	0	25,000	118,000
Utilised in the period	0	(118,000)	(118,000)	(96,714)
Release of provision for the period	0	0	0	(1,500)
Balance at 31 March 2018	25,000	0	25,000	118,000

	Legal Costs	Early retirement and reorganisation costs	2017/18 Totals	2016/17 Totals
	£	£	£	£
Analysis of expected timing of payment or release of provisions				
No later than one year	25,000	0	25,000	118,000
Later than one year and not later than five years	0	0	0	0
Later than five years	0	0	0	0
	25,000	0	25,000	118,000

12. Capital commitments

There were no capital commitments as at 31 March 2018 (2016/17 £Nil).

13. Commitments under leases

Operating leases

Total future minimum lease payments under operating leases are given in the table below.

	31 March 2018	31 March 2017
	£	£
Obligations under operating leases for the following periods are:		
Buildings		
Not later than one year	367,337	330,000
Later than one year not later than five years	649,696	907,500
	<u>1,017,033</u>	<u>1,237,500</u>
Other		
Not later than one year	5,393	5,393
Later than one year not later than five years	9,438	14,830
	<u>14,831</u>	<u>20,223</u>
	<u>1,031,864</u>	<u>1,257,723</u>

14. Contingent liabilities

The HFEA regulates a sector that addresses some highly charged issues, of both a personal and clinical nature, which may generate close scrutiny. Some of the projects and work that the HFEA has undertaken, as well as certain decisions that the HFEA has made may give rise to later challenge, including a risk of legal action.

At the date of finalising these accounts, there were two matters in litigation that may have financial consequences for the HFEA. For both, judgment is awaited and the liability will not be known until after then.

15. Related party transactions

a) The Department of Health and Social Care (DHSC) is regarded as a related party. During the period the HFEA had various material transactions with the DHSC and with some NHS trusts for which the Department of Health and Social Care is regarded as the parent department.

During the period the HFEA received £933,000 (2016/17 £1,033,000) from the DHSC in relation to operational grant-in-aid and £500,000 (2016/17 £467,000) cash allocation for capital expenditure; our IfQ programme. At the 31 March 2018 the HFEA had drawn down all of its cash allocation.

The DHSC invoiced the HFEA £31,723 in addition, we have accrued £4,200 in respect of internal audit work and recruitment services for the 2017/18 business year.

b) The National Institute for Health and Care Excellence (NICE) is regarded as a related party. During the period the HFEA had various material transactions with the NICE.

The NICE invoiced the HFEA £280,227 in relation to rent, rates and other facility costs. At 31 March 2018 we have accrued £100,473 representing rent and service charges for the last quarter of 2017/18. £Nil was due to the HFEA from the NICE.

c) The Human Tissue Authority (HTA) is regarded as a related party. During the period the HFEA had transactions with the HTA to the value of £99,497.

16. Events after the reporting period

The Accounting Officer authorised these financial statements for issue on the date on which the accounts are certified by the Comptroller and Auditor General.

CCS0618969246
978-1-5286-0626-4